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ABSTRACT
MicroRNAs (miRNAs) are potent negative regulators
of gene expression involved in all aspects of cell
biology. They finely modulate virtually all physio-
logical pathways in metazoans, and are deeply
implicated in all main pathologies, among which
cancer. Mir-221 and miR-222, two closely related
miRNAs encoded in cluster from a genomic region
on chromosome X, are strongly upregulated in
several forms of human tumours. In this work,
we report that the ectopic modulation of NF-kB
modifies miR-221/222 expression in prostate carcin-
oma and glioblastoma cell lines, where we had
previously shown their oncogenic activity. We
identify two separate distal regions upstream of
miR-221/222 promoter which are bound by the
NF-kB subunit p65 and drive efficient transcription
in luciferase reporter assays; consistently, the
site-directed mutagenesis disrupting p65 binding
sites or the ectopical inhibition of NF-kB activity sig-
nificantly reduce luciferase activity. In the most
distal enhancer region, we also define a binding
site for c-Jun, and we show that the binding of this
factor cooperates with that of p65, fully accounting
for the observed upregulation of miR-221/222. Thus
our work uncovers an additional mechanism
through which NF-kB and c-Jun, two transcription
factors deeply involved in cancer onset and pro-
gression, contribute to oncogenesis, by inducing
miR-221/222 transcription.
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs
working as post-transcriptional regulators of gene
expression through either the degradation or the impair-
ment of the translation of speciﬁc target messenger RNAs
(mRNAs) (1). A continuously increasing amount of
evidence is provided about the involvement of these
small regulators in virtually all aspects of cell biology,
including physiological modulation and pathological dis-
ruption of basic pathways. As an obvious consequence,
miRNAs are found to be key players in cancer, where
they regulate all main aspects of tumorigenesis and
tumor progression, from the ﬁrst initiating steps to metas-
tasis formation and spreading (2). Those miRNAs whose
expression is positively correlated with oncogenesis are
often dubbed ‘oncomiRs’. Among these, miR-221 and
miR-222 are a pair of miRNAs encoded in cluster on
chromosome X, widely overexpressed in a large variety
of human cancers, where they were shown to play their
oncogenic roles via the downregulation of several tumor
suppressors such as p27, p57, PTEN and many others
(3,4). In our previous work, we demonstrated that
miR-221 and miR-222 are overexpressed in prostate car-
cinoma and in glioblastoma (5–7), and in both tumors
they downregulate the cell cycle inhibitor p27 by impairing
the translation of its mRNA (6,7).
To date, the great amount of data describing the
tumor-speciﬁc modulation of some miRNAs is not yet
complemented by studies explaining the basis for the
aberrant expression of miRNAs in cancer. There is a
general agreement about miRNA gene transcription
being performed prevalently by RNA Polymerase II
(8,9), which implies that miRNA genes share many
common features with protein coding genes, such as
basic promoters, polyadenilation of the primary tran-
scripts and speciﬁc regulation by transcription factors
both at proximal promoters and at distal enhancers.
Two pleiotropic transcription factors deeply involved in
almost all aspects of human cancer, NF-kB and AP-1, are
good candidates as potent activators of oncogenic
miRNAs. NF-kB embraces a family of transcription
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including one subunit of p65 (relA) and another subunit
such as p50, c-rel or relB (10). The dimers are kept in an
inactive form in the cytoplasm by one of the members of
the IKB family, mainly IKBa. Phosphorylation and pro-
teasome degradation of IKBa sets NF-kB free to enter the
nucleus where it controls transcription of a wide variety of
genes (11). This activated form of NF-kB is upregulated
and functionally correlated with many tumors, including
glioblastoma, where it modulates proliferation and
invasion (12) and prostate carcinoma, where it marks
metastatic cancer (13). AP-1 is another example of
dimeric transcription factor containing members of
JUN, FOS, ATF and MAF proteins, all sharing a basic
leucine zipper motif needed for dimerization and DNA
binding (14). FOS and especially JUN are the main
members of the AP-1 family, primarily considered as
oncogenic activators, even with some interesting excep-
tions to this rule (15). AP-1 and speciﬁcally c-Jun,
affects tumor cell proliferation, migration and invasion
and inﬂuences also the proangiogenic potential of cancer
cells by inducing VEGF expression and other angiogenic
factors (14). Thus, like NF-kB, AP-1 takes an active part
throughout tumorigenesis from the beginning to distal
dissemination.
In the present study, we investigated the regulation of
miR-221 and miR-222 transcription in prostate carcinoma
and glioblastoma cell models. By bioinformatic predic-
tion, we identiﬁed two highly conserved genomic regions
upstream of miR-221/222, embedding NF-kB and c-Jun
responsive elements and we tested them in reporter assays
by which we conﬁrmed their transcriptional activation
function. The binding of p65 and c-Jun was assessed by
electrophoretic mobility shift assays (EMSA) and chroma-
tin immunoprecipitation (ChIP) experiments, while the
functional involvement of both NF-kB and c-Jun in
miR-221/222 expression was demonstrated by up- and
downregulating them via exogenous stimulation or
targeted silencing RNAs (siRNAs), respectively.
These results, as a whole, may uncover a new way by
which AP-1 and NF-kB contribute to tumorigenesis
in prostate carcinoma and glioblastoma, which is by
inducing the expression of the oncomiRs miR-221 and
miR-222.
MATERIALS AND METHODS
Cell lines, treatments and transfection
All cell lines were maintained in RPMI 1640 medium sup-
plemented with 10% heat-inactivated fetal bovine serum.
LNCaP cells were starved for 24h and then treated with
10ng/ml of TNF-a (SigmaAldrich). Transfections were
performed by Lipofectamine 2000 (Invitrogen) using
plasmid DNA in Opti-MEM I (Invitrogen), as recom-
mended by the manufacturer. For transient transfections,
reporter plasmids were co-transfected with a 1:7 relative
amount of the plasmid pEGFP-C3 (Clontech), to monitor
transfection efﬁciency. Cells were analyzed by ﬂuorescence
microscopy 48h after transfection to calculate the trans-
fection efﬁciency. For each well, the cell number in four
random microscopic ﬁelds was counted and transfection
efﬁciency for each sample was estimated as the mean value
of green ﬂuorescent protein expressing cells over 100 cells
per ﬁeld.
RNA isolation and quantitative real time polymerase
chain reaction
Total RNA was isolated from cells by TRIZOL reagent
(Invitrogen) as described by manufacturer’s instructions.
An amount of 0.05mg total RNA was reverse-transcribed
by using the Taqman MicroRNA Reverse Transcription
Kit (Applied Biosystems). Comparative real-time poly-
merase chain reaction (PCR) was performed in triplicate
with the use of the Taqman Universal PCR Master
Mix (Applied Biosystems) on the Applied Biosystems
7500 FAST real-time PCR System. Mature miRNA-
speciﬁc primers and probes were obtained from Applied
Biosystems. Normalization was performed by simultan-
eous quantiﬁcation of small endogenous nuclear RNA
U6 (RNU6B) and relative expression was calculated
employing the comparative CT method.
Luciferase reporter constructs and luciferase assay
Regions A and B were ampliﬁed by PCR from human
genomic DNA (regA primers: fw 50-agaatgccttagggtttt
ct-30,r v5 0-tcttatgaacttgattcct-30; regB primers: fw 50-ttct
gtttggtccttcctct-30,r v5 0-cattcggttgtgtagagcca-30). The
PCR products were cloned into the pGL3 promoter
Vector (Promega) using T4 DNA ligase (Fisher scientiﬁc).
All constructs were conﬁrmed by sequencing. Mutations
were introduced into the NF-kB and AP-1 binding sites
using the QuickChange Site-directed Mutagenesis Kit
(Stratagene). For luciferase activity measurement, the
Dual-Luciferase reporter assay system (Promega) was
used. PC3 and U87 cells were transfected with each
reporter construct and the TK-Renilla luciferase plasmid
that was used as a transfection control. Luciferase detec-
tion was performed 48h after reporter construct transfec-
tion. Expression was calculated as the relative Fireﬂy
luciferase activity normalized with respect to the activity
of transfection control Renilla luciferase. Reporter assays
were performed in triplicate.
Chromatin immunoprecipitation assay
Chromatin was prepared by the Millipore/Upstate ChIP
assay kit (Millipore) according to the manufacturer’s in-
struction. For each assay, a total of 10
7 cells were ﬁxed
with 1% of formaldehyde. Cell pellets were resuspended in
SDS lysis buffer. Samples were sonicated with a
Diagenode Bioruptor (Diagenode SA) for 12 cycles of
30s at high power, centrifuged and diluted 10-fold in
ChIP dilution buffer. After removing an aliquot
(whole-cell extract input), the chromatin samples were
incubated at 4 C overnight with antibodies against p65
(ab7970 abcam) or c-Jun (sc-8008 Santa Cruz),
Polymerase II (sc-55492, Santa Cruz), H3K4me1
(Millipore) or H3K9ac (Millipore). As controls, aliquots
of the same chromatins were processed in the same way,
but the speciﬁc antibodies were omitted from the reaction.
The samples were then precipitated by binding to protein
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Billerica, MA, USA) and treated as previously described
(16). The PCR primers (RegA primer: fw 50-ATCTTGTG
CCAACCAGTCCCTTCT-30,r v5 0-AACATTCTCTGG
GACGTTCCTGCT-30; regB primer fw 50-TGGTCCTT
CCTCTAAGATTGGTCC-30,r v5 0-ACCAAACTGCAG
GAACTGACTCAT-30; transcription start site (TSS)
primer: fw 50-GAAGGTGTAGGTACCCTCAA-30,r v
50-TCAACACAACTGCCTACTGC-30) were designed to
amplify 60–120bp fragments from selected genomic
regions. Real-time PCRs of genomic regions containing
the putative NF-kB and AP-1-binding site were performed
in triplicate by using Power SYBR green master mix
(Applied Biosystem). Cycling parameters were 50 C
2min, 95 C for 10min, followed by 38–42 cycles of 95 C
for 15s, 60 C 1min. Control ampliﬁcations were per-
formed with oligos 50-AAACCACCCATCCAGAAG
GG-30 and 50-CGTGGCAGCACTCGTAAGACT-30
(chr1:204,366,822–204,366,872) used as the negative
control (16). The relative occupancy of the immunopre-
cipitated factor at a locus was estimated by using the com-
parative threshold method (17).
Electrophoretic mobility shift assay
32P-labeled double-stranded oligonucleotides of
3.0 10
4cpm spanning the NF-kB sites of RegionA
(bsA: 50-GTTCTGGGATTTCCCCCGAT-30) or regionB
(bsB: 50-CAGCAGGAACGTCCCAGAGAA-30) were
incubated with 5mg of nuclear extract at room tem-
perature for 20min with 2mg of poly(dI-dC) in 50mM
NaCl, 10mM Tris pH 7.5, 1mM DTT and 20%
glycerol. Competition experiments were performed by
co-incubating the probe with 100-fold molar excess of un-
labeled double-stranded oligonucleotide or unlabeled
double- stranded oligonucleotide mutated in NF-kB sites
of regionA (mut-bsA: 50-GTTCTGAACGGGACCCCGA
T-30) or regionB (mut-bsB: 50-CAGCAGACCTTGTTCA
GAGAA-30). Supershift assays were performed by
incubating nuclear extracts with speciﬁc antibodies
against p65 (ab7970 abcam) for 30min at room tempera-
ture before the addition of the probe. Band shifts were
resolved on non-denaturing 4% polyacrylamide gels.
Immunoblot analysis and c-Jun knockdown
Immunoblot analysis was performed as described previ-
ously (7). SMARTpool siRNAs against c-Jun and
control siRNAs were obtained from Dharmacon and
transfected by Lipofectamine 2000 into PC3 and U87
cells at a ﬁnal concentration of 100nM.
Evaluation of NF-kB activity
NF-kB activity was measured in nuclear protein extracts
(15mg) by the TransAM
TM NF-kB p65 protein assay
(Active Motif, Carlsbad, CA, USA), an ELISA-based
method designed to speciﬁcally detect and quantify
NF-kB p65 subunit activation, with high sensitivity and
reproducibility. The assay was performed according to the
manufacturer’s protocol and analyzed using a microplate
absorbance reader Biorad680 (Biorad, CA, USA).
RESULTS
Impaired activation of NF-kB alters miR221/222
expression
We performed a bioinformatic search for transcription
factor binding sites (MatInspector software, http://www
.genomatix.de) in the human genomic sequence
( 12000bp) upstream of miR-222/221 transcriptional
unit (18) and identiﬁed predicted NF-kB binding sites
embedded in two regions highly conserved in mammals
(RegA and RegB, Figure 1A), as evidenced from Human
Mar. 2006 (NCBI36/hg18) assembly UCSC Genome
Browser (http://genome.ucsc.edu/). To verify the involve-
ment of NF-kB in miR-222/221 expression, we performed
experiments of induction/repression of the NF-kB
pathway in cell lines endogenously characterized by
either low/high NF-kB activity or low/high levels of
miR222/221 (5,7). First, we analyzed LNCaP prostate car-
cinoma cells that have low NF-kB activity (19) and low
levels of miR221/222 (7). After incubating these cells
with TNFa for 3h, we veriﬁed NF-kB activation (Figure
1B) by TransAM NF-kB p65 kit (Active Motif) and we
analyzed mir-222 and miR-221 by qRT-PCR. In these con-
ditions of NF-kB stimulation, we found an upregulation of
about 2-fold of both miRNAs (Figure 1C, left panel). We
then analyzed PC3 prostate carcinoma cells and U87 glio-
blastoma cells, both characterized by high NF-kB activity
(12,19) and high levels of miR221/222 (5,7). To inhibit
NF-kB pathway, we transfected these cells with
pCMV-IkBaM plasmid that encodes a dominant-negative
mutant of IkBa, thus blocking the phosphorylation events
that trigger NF-kB activation (Figure 1B). As shown in the
central and right panels of Figure 1C, the blockade of
NF-kB after pCMV-IkBaM transfection, decreased
miR-221/miR-222 expression of 50% in both cell lines.
Similar results were obtained when PC3 cells were
incubated in the presence of acetyl-b-boswellic acid (data
not shown) that in these cells inhibits the constitutively
activated NF-kB signaling (20). These results demonstrate
that the modulation of NF-kB pathway affects miR-221/
222 expression in prostate carcinoma and glioblastoma
cells, suggesting that NF-kB is involved in miR-221/222
expression regulation. We also showed the effects of
NF-kB inhibition on p27
Kip1 expression in PC3 and U87
cells, where we hadpreviously demonstrated that miR-221/
222 target p27 (7). We decided to measure the effects of
NF-kB in a reporter assay with a luciferase construct under
the control of p27 30-UTR (p30-UTR-p27). In this way, we
highlighted the effects on p27 30-UTR, where miR-221/222
work. The results we obtained (Figure 1D) show that the
downregulation of NF-kB is able to consistently
upregulate luciferase activity driven by p27 30-UTR,
strongly indicating that this effect is directly mediated by
miR-221/222.
Two regions upstream of miR-221/222 encoding sequence
embed NF-kB binding sites and are endowed with
NF-kB-dependent enhancer activity
In order to better investigate the role of NF-kB and to test
a putative enhancer activity of RegA and RegB, we
3894 Nucleic Acids Research, 2011,Vol.39, No. 9Figure 1. NF-kB modulates miR-221/222 expression through two genomic sites upstream of miR-221/222 transcriptional unit. (A) Schematic
diagram of Regions A (RegA) and B (RegB) genomic loci on human chromosome X derived from Human Mar. 2006 (NCBI36/hg18) assembly
UCSC Genome Browser. The direction of miR-221 and miR-222 transcription is indicated by an arrow. (B) NF-kB activity assay. LNCaP cells were
starved for 24h and then stimulated with TNFa for 3h. PC3 and U87 cells were transfected for 48h with the pCMV-IkBaM( + I kBaM) or pCMV
( IkBaM) plus pEFGP, to assess transfection efﬁciency. Nuclear protein extracts were harvested and NF-kB activity was measured by transAM
NFkB p65 protein kit. (C) Total RNA from LNCaP, PC3 and U87 cells treated as in (B) was extracted for quantitative real time polymerase chain
reaction (qRT-PCR) analysis, miRNAs were normalized to snoRNA U6. For each protocol, three experiments were performed independently and
the mean values (±SE) among experiments are presented. (D)p 3 0-UTR-p27 construct harboring the 30-UTR of p27
kip1, was transfected into PC3
and U87 cells after 24h of control (p30-UTR-p27) or pCMV-IkBaM (p30-UTR-p27+IkBaM) plasmids transfection. (E) Left panel: empty reporter
plasmid (c) or pRegA and pRegA-mp65 luciferase constructs containing, respectively, a wild-type and a mutated Region A were transfected into PC3
and U87 cells after 24h of control ( ) or pCMV-IkBaM( + I kBaM) plasmids transfection. Another complete set of samples was treated with TNFa
for 3h (+TNFa) in each cell line. Luciferase activity was determined 48h after reporter plasmid transfection in all cases. The ratio of normalized
sensor to control luciferase activity is shown. Right panel: the same set of experiments was performed for constructs pRegB and pRegB-mp65
harboring a wild-type or a mutated Region B, respectively. Data are presented as mean±SE from three separate experiments with at least n=3 for
each experiment.
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fragments corresponding to each region into the
pGL3-promoter vector that contains a minimal SV40
promoter upstream of luciferase cDNA. We transfected
the two plasmids named pRegA and pRegB for Regions
A and B, respectively, into PC3 and U87 cells (Figure 1E).
Luciferase assays showed that both regions actively
enhance transcription in both cell lines: pRegA yields a
 2-fold induction of luciferase activity compared with the
empty vector (Figure 1E, left panel), while pRegB is even
more effective, producing a 6-fold enhancement of
luciferase activity (Figure 1E, right panel). The introduc-
tion of point mutations disrupting the predicted NF-kB
binding site (pRegA-mp65, Figure 1E, left panel) restored
the luciferase levels to those of the empty vector in Region
A, while in Region B (pRegB-mp65, Figure 1E, right
panel) luciferase activity, even if signiﬁcantly reduced,
was still above the levels of the negative control, indicating
the presence of other relevant activation sites in that
region. A reduction of luciferase activity was achieved
even when the two cell lines were transfected with
pCMV-IkBaM plasmid 24h before pRegA and pRegB
transfection (+IkBaM, Figure 1E, in both panels, in
each cell line). As expected, IkBaM transfection did not
affect luciferase activity driven by the mutated constructs.
A further conﬁrmation of the involvement of the NF-kB
pathway in the transcriptional activity of RegA and RegB
was provided by treating PC3 and U87 cells with TNFa,
that in fact enhanced luciferase activity of both wild-type
constructs, but not of the mutated ones (+TNFa, Figure
1E, left and right panel). Altogether, these assays indicate
that Regions A and B own an intrinsic transcriptional
activation potential working in two different cancer cell
contexts and this likely relies on the predicted NF-kB sites
present in each region.
NF-kB is recruited at two regulatory regions upstream
of mir-222/221 locus
The reduction in transcriptional activity of both Regions
A and B observed when NF-kB sites were mutated as well
as in the presence of a dominant-negative mutant of IkBa
suggested that NF-kB directly binds those sites in Regions
A and B. To assess the ability of the two binding sites to
actually bind NF-kB nuclear protein, we performed
EMSA. As probes, we used sequences bsA and bsB cor-
responding to the NF-kB binding sites, respectively, in the
Regions A and B and the reaction was carried out in the
presence of either PC3 or U87 nuclear extracts. EMSA
revealed DNA–NF-kB-containing complexes on both se-
quences in both cell lines (Figure 2A and B). A speciﬁc
competition of the gel retardation was induced by the
co-incubation of labeled probes together with a 100-fold
molar excess of unlabeled bsA and bsB probes (Figure 2A,
Figure 2. NF-kB binding to Regions A and B. (A) Electrophoretic
mobility shift assay. Nuclear extracts were prepared as described in
the text, and assayed for protein binding to sequence bsA, correspond-
ing to NF-kB binding site in the Region A. An unlabeled bsA probe
(lane 4) or mut-bsA probe mutated in NF-kB site (lane 3) were used as
competitors. Where indicated, an antibody recognizing the NFk-B p65
subunit was included (lane 5). Products of binding reactions were
resolved by electrophoresis on 4% polyacrylamide gels and detected
by autoradiography. (B) The same set of experiments was performed
for Region B; competition with unlabeled wt probe (bsB) and mutated
probe (mut-bsB) are indicated in lanes 5 and 3, respectively. Supershift
with p65 antibody is evidenced in lane 4. (C) ChIP assay of chromatin
isolated from PC3 and U87 cell lines transfected with control (bsA and
bsB) or pCMV-IkBam (bsA+ IkBam and bsB+ IkBam) plasmids, and
immunoprecipitated by anti-p65 or control IgG, followed by qPCR
analysis with primers targeted to sequences bsA and bsB and to a
region on chromosome 1 used as the negative control (16). The data
show occupancy relative to control IgG and represent mean±SE of
three independent experiments.
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pothesis that NF-kB binds Regions A and B sites, we did
not detect any competition when the ‘cold’ competitors
used were the mutagenized sequences bsA or bsB, where
NF-kB sites were disrupted (Figure 2A, lanes 3 and Figure
2B, lanes 3). The speciﬁcity was conﬁrmed by supershift
with antibody anti-RelA/p65 (Figure 2A, lane 5 and
Figure 2B, lane 4).
Finally, the direct interaction between these putative
cis-regulatory elements and NF-kB was investigated by
ChIP assays. Isolated chromatin from PC3 and U87 cell
lines was immunoprecipitated by anti-RelA/p65 or control
IgG, followed by qPCR analysis with primers targeted to
sequences bsA and bsB and to a region on chromosome 1
(chr1:204,366,822–204,366,872), used as the negative
control (16). As shown in Figure 2C, p65 binds both
elements in both cell lines, with binding to the highly
conserved B region being always stronger. The speciﬁc
involvement of p65 was further conﬁrmed by experiments
carried out in pCMV-IkBaM transfected cells: the inhib-
ition of NF-kB pathway signiﬁcantly impaired p65
binding to both Regions A and B (Figure 2C). These
results demonstrate that NF-kB binds directly to the
identiﬁed sites in Regions A and B upstream of
miR-221/222 genomic region.
NF-kB and c-Jun bind together to one of the regulatory
regions upstream of miR-221/222 and cooperate to
induce transcription
MiRNA transcription, just like that of mRNAs, can be
co-regulated by more than one transcription factor,
working either in cooperation or independently. In fact,
our bioinformatic search for relevant transcription factors
revealed that Region B harbors a canonical AP-1 binding
site 115bp downstream the NF-kB bsB (Figure 3A). AP-1
is a dimeric basic leucine zipper protein that belongs to the
Jun and Fos subfamilies; c-Jun is the most potent tran-
scriptional activator in its group (21). Interestingly, a
recent paper demonstrated that c-Jun is involved in
miR-222/221 activation in lung and liver cancer (3). To
address the involvement of c-Jun in miR-221/222 activa-
tion in prostate carcinoma and in glioblastoma, we per-
formed a knockdown of c-Jun by siRNAs in U87 and PC3
cells and measured miR-221/222 expression by qRT-PCR
(Figure 3B). c-Jun depletion resulted in a 60–70%
decrease in miR-221 and miR-222 levels in both cell
lines (Figure 3B). In agreement with what we found by
inhibiting NF-kB, we observed that c-Jun depletion too
was able, per se, to increase the luciferase activity driven
by p27
kip1 30-UTR reporter construct (Figure 3C), again
showing that c-Jun can indirectly modulate p27 through
miR-221/222. Moreover, the concomitant downregulation
of c-Jun by siRNAs and of NF-kB by pCMV-IkBaM
plasmid transfection yielded a miR-221/222 reduction
stronger than any one obtained in either single
knockdown condition (i.e. c-Jun siRNAs or NF-kB inhib-
ition), thus indicating that NF-kB and AP-1 may cooper-
ate to the induction of miR-221/222 through binding
Region B in prostate carcinoma and glioblastoma. To
further assess the functional role of c-Jun in miR-221/
222 expression, we carried out ChIP assays measuring
the binding of c-Jun to Region B in PC3 and U87 cell
lines treated with control (bsB) or anti-c-Jun (bsB
+siRNA c-jun) siRNAs. Indeed, c-Jun binding was re-
markably enriched in Region B as compared to the
negative control region (Figure 3D) and no relevant chro-
matin enrichment by c-Jun ChIP was observed in c-Jun
depleted cells, testifying the speciﬁcity of the ChIP assay.
We also checked whether a previously identiﬁed AP-1 site
(3) found 130nt upstream of the 50-end of miR221/222
(Figure 3A and D,  130nt) is bound by c-Jun in PC3
and U87 cells, but we could not ﬁnd any signiﬁcant en-
richment in these contexts.
In order to directly link our results about c-Jun binding
to Region B with those showing that c-Jun is an activator
of miR-221/222 expression, we designed experiments to
prove that Region B works as an enhancer through both
its NF-kB and its AP-1 binding sites. As a ﬁrst approach,
we performed luciferase assays using pRegB plasmid,
pRegB mutagenized in c-Jun binding site (pRegB
mc-Jun) and pRegB mutagenized in both sites (pRegB
mp65/c-jun) (Figure 4A). Interestingly, the enhancer
activity of RegB was almost abolished when point muta-
tions disrupting the predicted c-Jun binding site were
introduced or when pRegB plasmid was transfected 24h
after siRNAs against c-Jun. Moreover, when we trans-
fected pRegB mp65/cjun, the effect of the mutagenesis in
both p65 and c-Jun sites was comparable with that
obtained by mutating the c-Jun site alone, suggesting
that c-Jun is necessary for the recruitment of NF-kB p65
to Region B. To better understand the relationship
between p65 and c-Jun in the binding of Region B, we
performed a ChIP assay in cells transfected with c-Jun
siRNAs, using an antibody against p65. As shown in
Figure 4B, in both PC3 and U87 cells, we conﬁrmed
that p65 is signiﬁcantly bound to Region B, but its
binding is strongly impaired by the siRNA-mediated de-
pletion of c-Jun. To further conﬁrm the speciﬁcity of this
c-Jun/p65 interaction for Region B, we assayed also the
binding of p65 to Region A in c-Jun depleted cells: p65
recruitment to Region A, where no predicted AP-1 site is
present, was not affected by c-Jun downregulation.
Finally, we performed a sequential ChIP experiment
where we ﬁrst immunoprecipitated chromatin with
anti-c-Jun antibodies, and then with anti-p65 ones; in
this way we were able to show that Region B simultan-
eously binds c-Jun and p65 (Figure 4C). As a whole, these
results show that p65 and c-Jun induce miR-221/222 ex-
pression by binding to Region B, and strongly indicate
that c-Jun is the main activator in this region, being ne-
cessary for p65 activation function.
P65 and c-Jun binding to Regions A and B modiﬁes the
local epigenetic state of the chromatin and induces
RNA Polymerase II recruitment to miR-221/222
transcriptional start site
To check if the binding of p65 and c-Jun to Regions A and
B can induce the recruitment of RNA Polymerase II to
miR-221/222 TSS, we performed ChIP assays for the
binding of RNA Polymerase II to the previously deﬁned
Nucleic Acids Research,2011, Vol.39, No. 9 3897TSS (18) and compared the results with those obtained in
cells transfected with pCMV-IkBaM plasmid or with
anti-c-jun siRNAs. As depicted in Figure 5A, RNA
Polymerase II binding to TSS is signiﬁcantly impaired
by NF-kB inhibition (TSS+IkBaM), and even more by
c-Jun depletion (TSS+siRNA c-jun). We then analyzed
some relevant epigenetic markers, such as the mono-
methylated form of histone H3 lysine 4 (H3K4me1) and
the acetylated form of histone H3 lysine 9 (H3K9ac), at
Regions A and B, as well as in TSS. Figure 5B shows that
H3K4me1 enrichment, typically associated with enhancers
(22), is reduced, in both Regions A and B, when NF-kB is
inhibited by IkBaM, whereas the siRNA-mediated
depletion of c-Jun inﬂuences only H3K4me1 enrichment
on Region B, as expected. Comparable results are shown
in Figure 5C concerning H3K9ac enrichment, except for
TSS: in this case H3K9ac is reduced by NF-kB inhibition
and almost totally knocked down by anti-c-jun siRNAs.
This is in agreement with the role of H3K9ac as a general
marker of open chromatin structure, while H3K4me1
preferentially marks enhancers (22). As a whole, these
data show that alterations of NF-kB or c-Jun activity
induce epigenetic modiﬁcations at Regions A and B
which are consistent with their role as enhancers, which
in turn can modulate RNA Polymerase II recruitment to
miR-221/222 TSS.
Figure 3. C-Jun binding to Region B. (A) Schematic representation of NF-kB (white rectangles) and c-Jun (white triangle) binding sites, inside
Regions A and B. (B) PC3 and U87 cells were transfected with control siRNAs or anti-c-JUN siRNAs and after 48h total RNA and proteins were
extracted. Levels of miR-221 and miR-222 were analyzed by qRT-PCR (left and central panels). The efﬁciency of siRNA-mediated depletion of c-Jun
was assessed by western blot (right panel). Western blot analysis of b-actin is shown as a loading control. (C)p 3 0-UTR-p27 construct harboring the
30-UTR of p27
kip1, was transfected into PC3 and U87 cells after 24h of control siRNA (p30-UTR-p27) or anti-c-JUN siRNAs (p30UTR-p27+siRNA
c-jun) transfection. (D) ChIP assay of chromatin isolated from PC3 and U87 cell lines transfected with control (bsB) or anti-c-Jun (bsB +siRNA
c-jun) siRNAs and immunoprecipitated by anti-c-Jun or control IgG, followed by qPCR analysis with primers targeted to sequence bsB or to a
sequence 130nt upstream of the 50-end of miR221/222 ( 130nt, black triangle in A) that represents a previously identiﬁed c-Jun site (3). The same
region shown in Figure 2C was used as the negative control. The data show occupancy relative to control IgG and represent mean±SE of three
independent experiments.
3898 Nucleic Acids Research, 2011,Vol.39, No. 9DISCUSSION
MiRNA genes, like protein-coding genes, are predomin-
antly transcribed by RNA Polymerase II, and own many
of the common features typical of RNA Pol II genes, such
as the regulation by core promoters and distal enhancers,
or the 50 capping and the polyadenilation of primary tran-
scripts (8,9). In this frame, a number of papers have been
published describing transcription factors that regulate
miRNA expression by binding to promoter regions, in
either physiological or pathological contexts (23,24).
Fewer works have recently described the role of enhancers
in the speciﬁc induction of miRNA expression (25,26).
In this study, we show that the transcription of
miR-221/222, whose promoter region had been previously
identiﬁed (3,18,27), is under the positive control of two
distal enhancer regions, binding NF-kB p65 and c-Jun,
which are known as ‘master regulators’ in cancer. We
identiﬁed these two regions, that we dubbed Regions A
and B, on the basis of their striking evolutionary
Figure 4. C-Jun is the main activator of Region B. (A) Empty reporter
plasmid (c) or pRegB, pRegB-mc-jun and pRegB mp65/c-jun luciferase
constructs containing, respectively, a wild-type, a mutated Region B in
c-Jun site or a mutated Region B in both p65 and c-Jun sites were
transfected into PC3 and U87 cells. pRegB was also transfected into
cells previously treated with anti-c-Jun siRNAs (pRegB+siRNA c-jun).
Luciferase activity was determined 48h after transfection. The ratio of
normalized sensor to control luciferase activity is shown and data are
represented as mean±SE from three separate experiments with at least
n=3 for each experiment. (B) ChIP assay was performed as described
in Figure 3C but the chromatin was immunoprecipitated by anti-p65
antibody and the data regarding bsA (bsA) or bsA in the presence of
anti-c-Jun siRNAs (bsA+siRNA c-jun) were included. (C) Sequential
ChIP assay performed in U87 cells on bsA (bsA) or bsB (bsB), by a
preliminary immunoprecipitation with anti-c-Jun antibodies, and a sub-
sequent one with anti-p65 antibodies. The data show occupancy relative
to control IgG and represent mean±SE of three independent
experiments.
Figure 5. Epigenetic modiﬁcations and RNA Polymerase II recruit-
ment at miR-221/222 regulatory regions. (A) ChIP assay of chromatin
isolated from U87 cells transfected with control (TSS), pCMV-IkBaM
(TSS+IkBam) or anti-c-Jun siRNAs (TSS+siRNA c-jun) and
immunoprecipitated by anti-POLII or control IgGs, followed by
qPCR analysis with primers targeted to miR-221/222 TSS or a
negative control region (16). The same chromatin as in (A) was
immunoprecipitated by anti-H3K4me1 (B) or anti-H3K9ac (C)
antibodies and qPCR analysis was performed with primers targeted
to the sequences bsA, bsB, TSS and negative control. The data show
occupancy relative to control IgGs and represent mean±SE of three
independent experiments.
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well conserved regions located upstream of miR-221/222
genomic sequence, those two were unique. In fact, they are
conserved in all species where miR-221/222 are present
and when we assayed each of them in transcription
reporter experiments, both of them behaved as good tran-
scriptional enhancers (Figure 1E). Our study is performed
in prostate carcinoma and glioblastoma cell lines, where
we and others demonstrated the oncogenic role of
miR-221/222 via the downregulation of p27, p57, PTEN
and other targets (3,4,6,7). In prostate carcinoma, NF-kB
is constitutively activated and represents a survival signal
sustaining tumor growth (28). Interestingly, the level of
NF-kB activation is directly proportional to tumor
aggressiveness; this is well represented also in vitro,b y
the differential activation of NF-kB that is detectable in
the highly aggressive PC3 cell line as compared with
LNCaP cells (19). Very recently, a prominent involvement
of NF-kB as a driver of metastasis has been uncovered in
prostate carcinoma (13). Glioblastoma provides a further
relevant example of tumor-speciﬁc activation of NF-kB,
which works as a signaling event mediating the effects of
PDGF (12). Here, we show that the ectopical modulation
of NF-kB in prostate carcinoma and glioblastoma cells
caused consistent changes in miR-221/222 transcription
(Figure 1C) through the binding to Regions A and B, as
conﬁrmed by mutagenis experiments where we disrupted
each of the p65 predicted sequences in Region A or in
Region B (Figure 1E). Consistently, when we impaired
NF-kB activation by the transfection of a dominant-
negative form of IkBa, we obtained comparable results,
again strongly suggesting that NF-kB works in the activa-
tion of miR-221/222 likely by binding to the two regions.
These results were further complemented by our EMSA
and ChIP experiments. However, in both tumor cell types,
Region B appeared to be more potent than Region A in
luciferase assays and, importantly, while the abolishment
of NF-kB site in Region A completely cancelled its tran-
scriptional activity, the mutation in Region B produced a
strong, but not total, reduction (Figure 1E). The presence
of a totally conserved c-Jun predicted site in Region B
prompted us to investigate c-Jun as an additional import-
ant candidate for miR-221/222 regulation operated
through Region B.
Indeed, a broad potential in tumor control is owned by
the members of AP-1 family, among which c-Jun is a
prominent representative (15): in human prostate cancer,
c-Jun is considered a marker of high risk tumors and
elevated levels of this transcription factor are associated
with disease recurrence (29). In glioblastoma cells, the
activated form of c-Jun favors cell survival and protects
tumor cells against the cytotoxic effects of DNA-
damaging agents (30). In fact, we demonstrated that
c-Jun is strongly involved in miR-221/222 transcription
enhancement, as indicated by the great reduction of
miR-221/222 expression in cells where we had depleted
c-Jun via siRNAs (Figure 3B). Accordingly, we showed
that the site-directed mutagenesis of c-Jun site completely
eliminated Region B activity in luciferase assays (Figure
4A), and in fact Region B is bound by c-Jun, as
demonstrated by our ChIP experiments (Figure 3D).
Thus, our ﬁndings correlating the high expression of
miR-221/222 in prostate and brain tumors with NF-kB
and c-Jun represent a novel case of concomitant and
possibly cooperative regulation of an oncogenic cluster
by these two factors. To our knowledge, only one work
has been published so far describing the concurrent action
of NF-kB p65 and AP-1 in the induction of a miRNA,
miR-155, via the recognition of close sites in the promoter
region (31). Like miR-221/222, miR-155 is one of the
miRNAs most frequently upregulated in cancer (32). In
mRNA genes, however, the functional interaction of
NF-kB and AP-1 is not uncommon, especially in the regu-
lation of tumor- or inﬂammation-related genes. In breast
cancer cells, the urokinase-type plasminogen activator
(uPA) gene, driving cancer cell motility and metastasis,
is induced by the conjunct work of AP-1 and NF-kB
(33). Another relevant example of a gene concomitantly
regulated by NF-kB and c-Jun is ccl2, a highly regulated
inﬂammatory gene strongly overexpressed in both
prostate carcinoma and glioblastoma (34,35), whose
promoter harbors c-Jun and NF-kB functional sites.
Notably, in that case the stronger enhancing effect was
demonstrated for c-Jun, needed for the recruitment of
NF-kB p65 (36). The performance of Regulatory Region
B that we are describing in our work shows some relevant
similarities with that pattern. In fact, luciferase reporter
and ChIP experiments have shown that the disruption of
the c-Jun recognition site has a much stronger effect than
that yielded by mutating the NF-kB one (Figures 1E and
4A). Most importantly, abolishing c-Jun binding by
anti-c-Jun-siRNAs affects p65 binding to its own site
too (Figure 4B). This implies that c-Jun is the major
player in Region B, where it helps also p65 binding. A
recent paper described that the transcriptional repression
of p27
Kip1 gene is mediated by AP-1 through the binding
of a site in p27
Kip1 promoter (37). A very intriguing hy-
pothesis is that AP-1 exerts an important and pleiotropic
role in the knockdown of p27 in cancer, both directly, by
repressing its transcription, and indirectly, by inducing its
negative regulators miR-221/222. In fact, we showed that
the siRNA-mediated inhibition of c-Jun induced an
upregulation of p27
Kip1 expression that was at least in
part mediated by miR-221/222 action on p27
Kip1
30-UTR (Figure 3C). The transcription activation poten-
tial of Region A, on the contrary, seems to be mostly due
to the NF-kB site that we have identiﬁed. In fact, both in
prostate carcinoma and in glioblastoma cells, the
site-directed mutagenesis of that site completely ﬂattens
down luciferase activity in reporter assays (Figure 2A).
NF-kB p65 involvement in the functional role of
miR-221/222 as repressors of p27
Kip1 was conﬁrmed
when we inhibited p65 activation by IkBaM and
observed an upregulation of the reporter activity yielded
by constructs harboring the 30-UTR of p27
Kip1 (Figure
1D). In 2008, Ozsolak et al. (38) demonstrated that an
MITF binding site is present in Region A, at a short
distance upstream of the NF-kB site identiﬁed by us.
This supports our deﬁnition of Region A as a relevant
regulatory region for miR-221/222, even if in our tumor
models a different factor, p65, is playing its role in place of
the melanoma-related MITF.
3900 Nucleic Acids Research, 2011,Vol.39, No. 9Previous studies on the transcriptional regulation of
miR-221/222 cluster were carried out in other human
cancers (3,18,27) and always led to the identiﬁcation of
promoter regions proximal to pre-miR-222 50-end. In
one paper, the MET oncogene was shown to activate
miR-221/222 in non-small cell lung cancer and in
hepatocellular carcinoma, through c-Jun recruitment to
a promoter region at  130bp upstream of pre-miR-222
50-end (3). This observation is in accordance with our
ﬁnding of c-Jun involvement in miR-221/222 upregulation
in cancer. However, in our tumor models, the c-Jun site
identiﬁed by Garofalo et al. (3) is not bound in ChIP ex-
periments, suggesting that in different tumor types the
same factor may use different sites to drive miR-221/222
transcription.
Our experiments describing the epigenetic state of
Regions A and B strongly indicate that they likely work
as enhancers when they are bound by NF-kB or c-Jun
(Figure 5), acting as long-distance inducers of RNA
Polymerase II recruitment at miR-221/222 TSS.
Moreover, our results about H3K4me1 and H3K9ac en-
richment at Regions A and B are in agreement with the
data presented in the Human Mar. 2006 (NCBI36/hg18)
assembly UCSC Genome Browser (http://genome.ucsc
.edu/) that indicate a clear gathering of H3K4me1 and
H3K9ac modiﬁcations at the same regions, even if in dif-
ferent cell contexts.
In conclusion, we think that our work opens a new per-
spective on miR-221/222 transcriptional regulation, by
linking these two proven oncomiRs with master transcrip-
tional regulators involved in cancer.
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